An increase in chiropractic co-management for urinary incontinence in males with prostate cancer undergoing androgen deprivation
therapy can help reduce the risk of spinal loss of bone mass density.
Testosterone breakthrough during LHRH agonist androgen deprivation
with curative radiation: Impact on PSA kinetics and subsequent biochemical outcomes.
All patients were subjected to medical castration/ androgen deprivation
therapy (ADT) with monthly 3.
Nead and colleagues evaluated medical records from the Stanford health system and New York's Mount Sinai Hospital for 16,888 nonmetastatic prostate cancer patients, of whom 2,397 received androgen deprivation
Currently, 6 months of androgen deprivation
therapy (ADT) plus radiotherapy is the standard treatment for unfavorable-risk localized prostate cancer.
Key clinical point: Androgen deprivation
therapy plus six cycles of docetaxel resulted in significantly longer overall survival compared with ADT alone in men with hormone-sensitive metastatic prostate cancer.
Enzalutamide will help patients with metastatic castration-resistant prostate cancer who still show signs of the condition after going through androgen deprivation
Therapy: An Essential Guide For Prostate Cancer Patients and Their Loved Ones
The pros and cons of different types of surgery, radiotherapy, brachytherapy, chemotherapy, and androgen deprivation
Thus, loss of filamin A allows these cells to survive androgen deprivation
, at and the cancer essentially becomes incurable.
Administering androgen deprivation
(hormone) therapy for prostate cancer intermittently rather than continuously may reduce side effects without significantly affecting a patient's survival, suggests a study published Sept.
therapy (ADT) is the mainstay treatment for men with advanced prostate cancer.
About 10-20% of patients are diagnosed with locally advanced or metastatic disease while others progress despite surgery, radiation and androgen deprivation
Because no adequate randomized trials have compared active treatments for localized prostate cancer, the authors analyzed risk-adjusted, cancer-specific mortality outcomes among men who underwent radical prostatectomy, external-beam radiation therapy, or primary androgen deprivation
Bone loss can be a significant side effect for older men undergoing androgen deprivation
therapy (ADT) for treatment of prostate cancer.